Decreased Expression of NPRL2 in Renal Cancer Cells is Associated with Unfavourable Pathological, Proliferation and Apoptotic Features

Pathology and Oncology Research

Volumn 20, Issue 4, 2014, Pages 829-837

  Tang, Yongyong ^a   Jiang, Li ^a   Tang, Wei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; NPRL2; Proliferation; Renal cancer carcinoma; Transfection

Indexed keywords

MESSENGER RNA; NPRL2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; APOPTOSIS; CANCER GRADING; CANCER STAGING; CELL CYCLE; CELL PROLIFERATION; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW UP; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL CULTURE; TUMOR INVASION; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL CYCLE; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84936074487     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9761-2     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
2. Campbell SC, Novick AC (2002) Renal tumors. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds) Kavoussi LR, Novick AC, Partin AW, Peters CA (ed.), Campbell’s urology. Elsevier, Philadelphia, pp 2672–2686
3. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96
4. Arsanious A, Bjarnason GA, Yousef GM (2009) From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer 8(1):20
5. Jiang Z, Chu PG, Woda BA, Liu Q, Balaji KC, Rock KL, Wu CL (2008) Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res 14:5579–5584
6. Lee JW, Bae SH, Jeong JW et al (2004) Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 36(1):1–12
7. Hirota, Yan L, Tsunoda T et al (2006) Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol 29(4):799–827
8. Lerman MI, Minna JD (2000) The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 60(21):6116–6133
9. Li J, Wang F, Haraldson et al (2004) Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res 64(18):6438–6443
10. Sasatomi E, Finkelstein SD, Woods JD et al (2002) Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. Cancer Res 62(9):2681–2689
11. Senchenko VN, Anedchenko EA, Kondratieva TT et al (2010) Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. BMC Cancer 10:75
12. Otani S, Takeda S, Yamada S, Sakakima Y et al (2009) The tumor suppressor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor. J Surg Oncol 100(5):358–363
13. Zabarovsky ER, Lerman MI, Minna JD (2002) Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21(45):6915–6935
14. Yi Lo PH, Chung Leung AC, Xiong W et al (2006) Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas. Cancer Lett 234(2):184–192
15. Chow LS, Lo KW, Kwong J et al (2004) RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer 109(6):839–847
16. Li J, Wang F, Protopopov A et al (2004) Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene. Oncogene 23(35):5941–5949
17. Wang F, Grigorieva EV, Li J et al (2008) HYAL1 and HYAL2 inhibit tumour growth in vivo but not in vitro. PLoS One 3(8):e3031
18. Senchenko et al (2010) Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. BMC Cancer 10:75
19. Jayachandran G, Ueda K, Wang B, Roth JA, Ji L (2010) NPRL2 sensitizes human non-small cell lung (NSCLC) cells to cisplatin treatment by regulating components in the DNA repair pathway. PLoS One 5(8):e11994
20. Otani S, Takeda S, Yamada S et al (2009) The tumor suppressor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor. J Surg Oncol 100:358–363
21. Edge SB, Byrd DR, Compton CC et al (2009) AJCC cancer staging manual, 7th edn. Springer Verlag, New York
22. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. IARC Press, Lyon, pp 16–18
23. Xue et al (2012) Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med 10:200
24. Otani S, Takeda S, Yamada S et al (2009) The tumor supperessor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor. J Surg Oncol 100(5):358–363
25. Gao Y, Wang J, Fan G (2012–2013) NPRL2 is an independent prognostic factor of osteosarcoma. Cancer Biomark 12(1):31–36
26. Yogurtcu B, Hatemi I, Aydin I et al (2012) NPRL2 gene expression in the progression of colon tumors. Genet Mol Res 11(4):4810–4816
27. Ji L, Nishizaki M, Gao B et al (2002) Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 62(9):2715–2720
28. Parasons SL, Watson SA, Brown PD et al (1997) Matrix metalloproteinases. Br J Surg 84(2):160–166
29. Economidou F, Tzortzaki EG, Schiza S et al (2007) Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions. Oncol Rep 18(6):1507–1512
30. Castagnaro A, Marangio E, Verduri A et al (2007) Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. Exp Lung Res 33(6):289–301
31. Kurata A, Katayama R, Watanabe T et al (2008) TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling. Cancer Sci 99(9):1827–1834
32. Kim JH, Kim H, Lee KY et al (2006) Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk. Hum Mol Genet 15(7):1181–1186
33. Wang YX, Zhu SC, Feng W, Li J, Su JW, Li R (2006) Effect on retardation of G2/M phase in esophageal carcinoma cells transfected with CHK1 and CHK2 shRNA after irradiation. Zhonghua Zhong Liu Za Zhi 28(8):572–577